Testosterone Gel Pump Dosing
Starting Dose
For testosterone gel pumps, begin with 40.5 mg of testosterone (2 pump actuations) applied once daily in the morning to the shoulders and upper arms. 1
- AndroGel 1.62% delivers 20.25 mg of testosterone per pump actuation, so the starting dose requires 2 actuations totaling 40.5 mg daily 1
- Fortesta 2% gel delivers 10 mg per pump actuation, with a typical starting dose of 40 mg daily (4 actuations) 2
- Axiron 2% solution delivers 30 mg per pump actuation, with a starting dose of 60 mg daily (2 actuations) applied to the axilla 2
Application Technique
- Apply to clean, dry, intact skin of the shoulders and upper arms only—never to the abdomen, genitals, chest, armpits, or knees 1
- Distribute the gel across the maximum surface area that will be covered by a short-sleeve t-shirt 1
- Prime the pump before the first use by depressing the actuator 3 times and discarding that gel 1
- Allow the application site to dry completely, then cover with clothing to minimize transfer risk 1
- Avoid swimming, showering, or washing the site for at least 2 hours after application 1
Dose Titration Schedule
Measure serum testosterone at 14 days and 28 days after starting therapy, then adjust the dose in 20.25 mg increments based on pre-dose morning levels. 1
Titration Algorithm (FDA-Approved for 1.62% Gel)
| Pre-Dose Morning Testosterone | Action |
|---|---|
| > 750 ng/dL | Decrease daily dose by 20.25 mg (1 pump actuation) [1] |
| 350–750 ng/dL | Continue current dose—no change [1] |
| < 350 ng/dL | Increase daily dose by 20.25 mg (1 pump actuation) [1] |
- The dose range for 1.62% gel is 20.25 mg (1 actuation) to 81 mg (4 actuations) daily 1
- For other gel formulations, the typical dose range is 50–100 mg daily for 1% gels and 10–70 mg daily for Fortesta 2% 2
Long-Term Monitoring
- After achieving stable levels, measure testosterone every 6–12 months 3, 4
- Target the mid-normal range of 400–700 ng/dL to balance efficacy and safety 3, 5
- For transdermal gels, draw the sample any time after ≥1 week of continuous use to reflect steady-state concentrations 3, 5
Safety Monitoring
Hematocrit Surveillance
- Check hematocrit at baseline, 3–6 months, and annually thereafter 3, 6
- Stop testosterone immediately if hematocrit exceeds 54%, evaluate for hypoxia or sleep apnea, and restart only after normalization at a reduced dose 3, 6
- Transdermal gels carry an 11.3–17.9% risk of elevated hematocrit, substantially lower than the 43.8% risk with injectable testosterone 6
Prostate Monitoring (Men ≥40 Years)
- Obtain baseline PSA and digital rectal exam before starting therapy 3
- Repeat PSA at 3–6 months and then annually 3
- Refer to urology if PSA rises >1.4 ng/mL within 12 months, PSA velocity >0.4 ng/mL/year, or digital exam is abnormal 3
Secondary Exposure Prevention
- Children and women must avoid contact with unwashed or unclothed application sites because skin-to-skin transfer can cause virilization in children and hormonal effects in women 1
- Patients should wash hands immediately after application and cover the site with clothing once dry 1
Common Pitfalls
- Do not apply gel to the abdomen—abdominal application reduces testosterone bioavailability by 30–40% compared with arm/shoulder application 7
- Do not sample testosterone at the wrong time—for gels, any time after 1 week of use is acceptable, but avoid sampling immediately after application 3, 5
- Do not ignore formulation differences—doses and application sites for 1%, 1.62%, and 2% gels are not interchangeable 1
- Do not continue therapy without symptom improvement—if testosterone levels normalize but symptoms persist after 3–6 months, consider discontinuing therapy 4